CRANBURY, NJ — Solco Healthcare is proud to announce its FDA approval for Telmisartan tablets, 20mg, 40mg and 80mg, which are AB-rated equivalents to Micardis® by Boehringer Ingelheim. “This recent approval continues to support Solco’s ability to provide high quality, cost effective medications to those in need,” said Hai Wang, President of Solco Healthcare. Telmisartan tablets
Read more
CRANBURY, NJ – Solco Healthcare U.S. is proud to announce that the U.S. Food and Drug Administration (FDA) approved its generic equivalent of Abilify® Tablets (Aripiprazole tablets), 2, 5, 10, 15, 20 and 30mg. The product is available for shipment now. Aripiprazole tablets are are indicated for the following: (A) Bipolar I disorder, (B) Irritability, associated
Read more
CRANBURY, NJ., April 25, 2018 – Solco Healthcare is proud to announce the launch of Entecavir Tablets, 0.5mg and 1mg, a generic equivalent of Baraclude® Tablets by Bristol-Myers Squibb Company. Solco is offering Entecavir Tablets, 0.5mg and 1mg, in 30-count bottles to its customers. The product is available for shipment immediately. Entecavir tablets are used to treat chronic
Read more
Cranbury, NJ., April 3, 2018. Solco Healthcare announced today the launch of Clonidine Hydrochloride Extended-Release Tablets, 01.mg, a generic version of Kapvay® Tablets by Concordia Pharmaceuticals Inc. The product is used for the treatment of attention-deficit/hyperactivity disorder (ADHD). The U.S. Food and Drug Administration (FDA) has granted final approval of its Abbreviated New Drug Application for Clonidine
Read more